5-HT4 receptor agonist and gastrokinetic agent. Stimulates intestinal acetylcholine release, possibly via 5-HT4 receptor-dependent and -independent mechanisms, leading to increased intestinal motility.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 465.95. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.15 mL||10.73 mL||21.46 mL|
|5 mM||0.43 mL||2.15 mL||4.29 mL|
|10 mM||0.21 mL||1.07 mL||2.15 mL|
|50 mM||0.04 mL||0.21 mL||0.43 mL|
References are publications that support the biological activity of the product.
Briejer et al (1993) Cisapride and a structural analogue, R 76,186, are 5-hydroxytryptamine4 (5-HT4) receptor agonists on the guinea-pig colon ascendens. Naunyn Schmiedebergs Arch.Pharmacol. 347 464 PMID: 8321323
Schuurkes et al (1985) Motor-stimulating properties of cisapride on isolated gastrointestinal preparations of the guinea pig. J.Pharmacol.Exp.Ther. 234 775 PMID: 3897516
Taniyama et al (1991) Cisapride stimulates motility of the intestine via the 5-hydroxytryptamine receptors. J.Pharmacol.Exp.Ther. 258 1098 PMID: 1890614
If you know of a relevant reference for Cisapride, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Cisapride, Cisapride supplier, 5-HT4, agonists, stimulates, Serotonin, Receptors, 5-Hydroxytryptamine, stimulate, ACh, acetylcholine, release, nicotinic, muscarinic, nAChR, R51619, R, 51619, Other, Acetylcholine, Non-selective, Muscarinics, 1695, Tocris Bioscience
4 Citations for Cisapride
Citations are publications that use Tocris products. Selected citations for Cisapride include:
Xiang et al (2005) Modulation of spontaneous firing in rat subthalamic neurons by 5-HT receptor subtypes. J Neurophysiol 93 1145 PMID: 15738272
Padayatti et al (2013) A hybrid structural approach to analyze ligand binding by the serotonin type 4 receptor (5-HT4). Mol Cell Proteomics 12 1259 PMID: 23378516
Beattie et al (2011) The Pharmacology of TD-8954, a Potent and Selective 5-HT(4) Receptor Agonist with Gastrointestinal Prokinetic Properties. Front Pharmacol 2 25 PMID: 21687517
Murray et al (2011) Polysynaptic excitatory postsynaptic potentials that trigger spasms after spinal cord injury in rats are inhibited by 5-HT1B and 5-HT1F receptors. J Neurophysiol 106 925 PMID: 21653728
Do you know of a great paper that uses Cisapride from Tocris? Please let us know.
Reviews for Cisapride
There are currently no reviews for this product. Be the first to review Cisapride and earn rewards!
Have you used Cisapride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
5-HT Receptors Scientific Review
Written by Nicholas M. Barnes and John F. Neumaier, this review summarizes the various serotonin receptor subtypes and their importance in mediating the role of serotonin in numerous physiological and pharmacological processes. Compounds available from Tocris are listed.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.